← Leaderboards
Edmund C. Lattime
Rutgers Biomedical And Health Sciences
$9,980,995
Attributed
$11,686,037
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,686,037 · 14
By mechanism
R01$7,300,065 · 5
N01$1,143,627 · 1
P30$980,707 · 4
T32$960,870 · 1
S10$500,000 · 1
R21$489,618 · 1
Top collaborators
- Shridar Ganesan4 shared
- Eileen White4 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Loren W Runnels$6,224,385
- Mladen Roko Rasin$4,645,787
- Janet Alder$2,120,579
- Tracy E Scott$574,720
- Maria Gloria Dominguez-Bello$829,727
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsBaseClinical TrialsGenerationsMalignant NeoplasmsTumor AntigensResearch PersonnelResponseHost Neoplasm InteractionUniversitiesFundingMemberCancer Institute Of New JerseyTrainingCancer Center Support GrantServicesImmuneResource SharingVaccinia VirusMethodologyInterestTranslatingGrowth
Grant awards (47)
Cancer Research Training and Education Coordination$269,566
P30 · FY2025 · CA · contact PI
Cancer Research Training and Education Coordination$49,294
P30 · FY2024 · CA · contact PI
Impact of mutation burden on cancer growth and the immune landscape$635,557
R01 · FY2023 · CA
Flow Cytometry and Cell Sorting$90,213
P30 · FY2023 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$83,276
P30 · FY2023 · CA · contact PI
Impact of mutation burden on cancer growth and the immune landscape$633,201
R01 · FY2022 · CA
Flow Cytometry and Cell Sorting$39,921
P30 · FY2022 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$32,983
P30 · FY2022 · CA · contact PI
Impact of mutation burden on cancer growth and the immune landscape$644,404
R01 · FY2021 · CA
Flow Cytometry and Cell Sorting$59,641
P30 · FY2021 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$49,339
P30 · FY2021 · CA · contact PI
Impact of mutation burden on cancer growth and the immune landscape$644,401
R01 · FY2020 · CA
Flow Cytometry and Cell Sorting$62,965
P30 · FY2020 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$49,325
P30 · FY2020 · CA · contact PI
Flow Cytometry and Cell Sorting$41,482
P30 · FY2019 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$30,488
P30 · FY2019 · CA · contact PI
TGFBeta Receptor Mutations in Cancer and Other Diseases$258,681
R01 · FY2012 · CA · contact PI
In-situ activation of antitumor effectors$246,522
R01 · FY2012 · CA · contact PI
In-situ activation of antitumor effectors$58,252
R01 · FY2012 · CA · contact PI
TGFBeta Receptor Mutations in Cancer and Other Diseases$36,523
R01 · FY2012 · CA · contact PI
In-situ activation of antitumor effectors$304,774
R01 · FY2011 · CA · contact PI
Targeting Transforming Growth Factor-beta in Metastatic Breast Cancer$287,952
R01 · FY2011 · CA · contact PI
TGFBeta Receptor Mutations in Cancer and Other Diseases$273,797
R01 · FY2011 · CA · contact PI
TAS::75 0849::TAS$999,908
N01 · FY2010 · CA · contact PI
In-situ activation of antitumor effectors$314,200
R01 · FY2010 · CA · contact PI
TAS::75 0849::TAS$143,719
N01 · FY2010 · CA · contact PI
Fluorescence Activated Cell Sorter$500,000
S10 · FY2009 · RR · contact PI
In-situ activation of antitumor effectors$151,545
R01 · FY2009 · CA · contact PI
In-situ activation of antitumor effectors$314,200
R01 · FY2008 · CA · contact PI
In-situ activation of anti-tumor effectors$311,150
R56 · FY2007 · CA · contact PI
Intravesical rF-GMCSF and rF-TRICOM in the treatment of advanced bladder cancer$241,207
R21 · FY2007 · CA · contact PI
Training Program in Translational Research in Cancer$218,184
T32 · FY2007 · CA · contact PI
CORE--LABORATORY SUPPORT SERVICES$122,214
P30 · FY2007 · CA · contact PI
In-situ activation of antitumor effectors$304,071
R01 · FY2006 · CA · contact PI
Intravesical rF-GMCSF and rF-TRICOM in the treatment of advanced bladder cancer$248,411
R21 · FY2006 · CA · contact PI
Training Program in Translational Research in Cancer$220,778
T32 · FY2006 · CA · contact PI
In-situ activation of antitumor effectors$311,389
R01 · FY2005 · CA
Training Program in Translational Research in Cancer$176,589
T32 · FY2005 · CA
In-situ activation of antitumor effectors$311,389
R01 · FY2004 · CA
Training Program in Translational Research in Cancer$220,778
T32 · FY2004 · CA
In-situ activation of antitumor effectors$311,389
R01 · FY2003 · CA
Training Program in Translational Research in Cancer$124,541
T32 · FY2003 · CA
In-situ activation of antitumor effectors$311,890
R01 · FY2002 · CA
HUMAN ANTITUMOR EFFECTOR MECHANISMS$242,318
R01 · FY2001 · CA
IN SITU ACTIVATION OF ANTITUMOR EFFECTORS$237,086
R01 · FY2001 · CA
HUMAN ANTITUMOR EFFECTOR MECHANISMS$235,260
R01 · FY2000 · CA
IN SITU ACTIVATION OF ANTITUMOR EFFECTORS$231,264
R01 · FY2000 · CA